Kiniksa Pharmaceuticals International Plc

KNSANASDAQ · USD
74.67USD-1.41 (-1.86%)
6310

Kiniksa Pharmaceuticals International Plc (KNSA) Options Open Interest

KNSA options open interest is 2,730 contracts. The 2-week average daily volume is 798 contracts across the chain.

Read more

Monitoring KNSA open interest helps you see where real money is positioned on Kiniksa Pharmaceuticals International Plc's options and which strikes are attracting the most commitment from traders. Kiniksa Pharmaceuticals International Plc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor KNSA options open interest in real time and find the strikes that matter.

Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising KNSA options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Kiniksa Pharmaceuticals International Plc to settle.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where KNSA open interest is concentrated. Our scanner maps Kiniksa Pharmaceuticals International Plc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Kiniksa Pharmaceuticals International Plc's options open interest as the signal it is, not as an afterthought.

2026-10-16
Calls
65.009.6014.0011.8054%+0.8935383
85.00—1.101.1051%+0.213562
80.001.003.002.0046%+0.359359
60.0014.0018.7016.3553%+0.970235
75.002.306.404.3549%+0.578625
Puts
75.000.504.002.2538%-0.411061
55.00—2.902.90159%-0.15295
80.004.007.805.9048%-0.63145
40.00—4.904.90318%-0.11314
45.00—4.904.90275%-0.13294

As of September 23, 2026

Follow the money

Track KNSA open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.

Start your 14-day free trial